nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—ALB—hematologic cancer	0.165	1	CbGaD
Bismuth Subsalicylate—PTGS2—Lenalidomide—hematologic cancer	0.0887	0.181	CbGbCtD
Bismuth Subsalicylate—PTGS2—Thalidomide—hematologic cancer	0.0474	0.0965	CbGbCtD
Bismuth Subsalicylate—PTGS1—Bortezomib—hematologic cancer	0.0459	0.0935	CbGbCtD
Bismuth Subsalicylate—PTGS1—Thalidomide—hematologic cancer	0.04	0.0815	CbGbCtD
Bismuth Subsalicylate—PTGS1—Ifosfamide—hematologic cancer	0.0352	0.0717	CbGbCtD
Bismuth Subsalicylate—PTGS1—Imatinib—hematologic cancer	0.0336	0.0685	CbGbCtD
Bismuth Subsalicylate—PTGS2—Triamcinolone—hematologic cancer	0.0328	0.0669	CbGbCtD
Bismuth Subsalicylate—PTGS2—Betamethasone—hematologic cancer	0.0282	0.0574	CbGbCtD
Bismuth Subsalicylate—ALB—Imatinib—hematologic cancer	0.0251	0.0512	CbGbCtD
Bismuth Subsalicylate—PTGS2—Cisplatin—hematologic cancer	0.0203	0.0413	CbGbCtD
Bismuth Subsalicylate—PTGS2—Etoposide—hematologic cancer	0.0199	0.0406	CbGbCtD
Bismuth Subsalicylate—PTGS1—Etoposide—hematologic cancer	0.0168	0.0343	CbGbCtD
Bismuth Subsalicylate—ALB—Prednisone—hematologic cancer	0.0166	0.0337	CbGbCtD
Bismuth Subsalicylate—PTGS2—Dexamethasone—hematologic cancer	0.0164	0.0334	CbGbCtD
Bismuth Subsalicylate—ALB—Irinotecan—hematologic cancer	0.0157	0.032	CbGbCtD
Bismuth Subsalicylate—PTGS2—ovarian follicle—hematologic cancer	0.00833	0.252	CbGeAlD
Bismuth Subsalicylate—ALB—Methotrexate—hematologic cancer	0.00831	0.0169	CbGbCtD
Bismuth Subsalicylate—TF—hematopoietic system—hematologic cancer	0.00355	0.107	CbGeAlD
Bismuth Subsalicylate—TF—gonad—hematologic cancer	0.0027	0.0817	CbGeAlD
Bismuth Subsalicylate—TF—blood—hematologic cancer	0.00235	0.0712	CbGeAlD
Bismuth Subsalicylate—TF—bone marrow—hematologic cancer	0.00227	0.0689	CbGeAlD
Bismuth Subsalicylate—TF—lung—hematologic cancer	0.00206	0.0624	CbGeAlD
Bismuth Subsalicylate—TF—testis—hematologic cancer	0.00194	0.0589	CbGeAlD
Bismuth Subsalicylate—TF—lymph node—hematologic cancer	0.00141	0.0427	CbGeAlD
Bismuth Subsalicylate—PTGS1—hematopoietic system—hematologic cancer	0.00105	0.0319	CbGeAlD
Bismuth Subsalicylate—ALB—testis—hematologic cancer	0.00101	0.0306	CbGeAlD
Bismuth Subsalicylate—PTGS2—hematopoietic system—hematologic cancer	0.001	0.0305	CbGeAlD
Bismuth Subsalicylate—ALB—lymph node—hematologic cancer	0.000733	0.0222	CbGeAlD
Bismuth Subsalicylate—PTGS1—blood—hematologic cancer	0.000697	0.0211	CbGeAlD
Bismuth Subsalicylate—PTGS2—blood—hematologic cancer	0.000666	0.0202	CbGeAlD
Bismuth Subsalicylate—PTGS2—bone marrow—hematologic cancer	0.000644	0.0195	CbGeAlD
Bismuth Subsalicylate—PTGS1—lung—hematologic cancer	0.000611	0.0185	CbGeAlD
Bismuth Subsalicylate—PTGS2—lung—hematologic cancer	0.000584	0.0177	CbGeAlD
Bismuth Subsalicylate—PTGS1—testis—hematologic cancer	0.000576	0.0175	CbGeAlD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	0.000503	0.209	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	0.000503	0.209	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	0.000492	0.205	CbGdCrCtD
Bismuth Subsalicylate—PTGS1—lymph node—hematologic cancer	0.000418	0.0127	CbGeAlD
Bismuth Subsalicylate—PTGS2—lymph node—hematologic cancer	0.000399	0.0121	CbGeAlD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	0.000304	0.126	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	0.000304	0.126	CbGdCrCtD
Bismuth Subsalicylate—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	0.000297	0.124	CbGdCrCtD
Bismuth Subsalicylate—Rash—Bleomycin—hematologic cancer	7.48e-05	0.000386	CcSEcCtD
Bismuth Subsalicylate—Pain—Cisplatin—hematologic cancer	7.47e-05	0.000385	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Bleomycin—hematologic cancer	7.47e-05	0.000385	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vinorelbine—hematologic cancer	7.42e-05	0.000383	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Gemcitabine—hematologic cancer	7.41e-05	0.000382	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Thalidomide—hematologic cancer	7.37e-05	0.00038	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Thiotepa—hematologic cancer	7.37e-05	0.00038	CcSEcCtD
Bismuth Subsalicylate—Rash—Vinorelbine—hematologic cancer	7.36e-05	0.00038	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vinorelbine—hematologic cancer	7.35e-05	0.000379	CcSEcCtD
Bismuth Subsalicylate—Headache—Vinorelbine—hematologic cancer	7.31e-05	0.000377	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—hematologic cancer	7.3e-05	0.000377	CcSEcCtD
Bismuth Subsalicylate—Oedema—Triamcinolone—hematologic cancer	7.26e-05	0.000375	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Alitretinoin—hematologic cancer	7.25e-05	0.000374	CcSEcCtD
Bismuth Subsalicylate—Infection—Triamcinolone—hematologic cancer	7.21e-05	0.000372	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Cisplatin—hematologic cancer	7.2e-05	0.000371	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—hematologic cancer	7.18e-05	0.00037	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Ifosfamide—hematologic cancer	7.17e-05	0.00037	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Thalidomide—hematologic cancer	7.13e-05	0.000368	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Etoposide—hematologic cancer	7.12e-05	0.000367	CcSEcCtD
Bismuth Subsalicylate—Nausea—Bortezomib—hematologic cancer	7.1e-05	0.000366	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Methotrexate—hematologic cancer	7.09e-05	0.000366	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Thiotepa—hematologic cancer	7.08e-05	0.000366	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Carmustine—hematologic cancer	7.08e-05	0.000365	CcSEcCtD
Bismuth Subsalicylate—Nausea—Bleomycin—hematologic cancer	7.04e-05	0.000363	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—hematologic cancer	7.03e-05	0.000363	CcSEcCtD
Bismuth Subsalicylate—Erythema—Prednisone—hematologic cancer	7.03e-05	0.000363	CcSEcCtD
Bismuth Subsalicylate—Rash—Thiotepa—hematologic cancer	7.03e-05	0.000362	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Thiotepa—hematologic cancer	7.02e-05	0.000362	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Alitretinoin—hematologic cancer	7.02e-05	0.000362	CcSEcCtD
Bismuth Subsalicylate—Headache—Thiotepa—hematologic cancer	6.98e-05	0.00036	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Etoposide—hematologic cancer	6.96e-05	0.000359	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Ifosfamide—hematologic cancer	6.93e-05	0.000358	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vinorelbine—hematologic cancer	6.93e-05	0.000358	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Cisplatin—hematologic cancer	6.91e-05	0.000356	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Thalidomide—hematologic cancer	6.85e-05	0.000354	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Carmustine—hematologic cancer	6.84e-05	0.000353	CcSEcCtD
Bismuth Subsalicylate—Constipation—Etoposide—hematologic cancer	6.84e-05	0.000353	CcSEcCtD
Bismuth Subsalicylate—Pain—Etoposide—hematologic cancer	6.84e-05	0.000353	CcSEcCtD
Bismuth Subsalicylate—Rash—Thalidomide—hematologic cancer	6.8e-05	0.000351	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Thalidomide—hematologic cancer	6.79e-05	0.00035	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Alitretinoin—hematologic cancer	6.78e-05	0.00035	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vincristine—hematologic cancer	6.76e-05	0.000349	CcSEcCtD
Bismuth Subsalicylate—Headache—Thalidomide—hematologic cancer	6.75e-05	0.000348	CcSEcCtD
Bismuth Subsalicylate—Pain—Prednisolone—hematologic cancer	6.75e-05	0.000348	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Methotrexate—hematologic cancer	6.75e-05	0.000348	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Ifosfamide—hematologic cancer	6.7e-05	0.000346	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—hematologic cancer	6.64e-05	0.000343	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—hematologic cancer	6.64e-05	0.000342	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Gemcitabine—hematologic cancer	6.63e-05	0.000342	CcSEcCtD
Bismuth Subsalicylate—Nausea—Thiotepa—hematologic cancer	6.62e-05	0.000341	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Etoposide—hematologic cancer	6.6e-05	0.00034	CcSEcCtD
Bismuth Subsalicylate—Oedema—Betamethasone—hematologic cancer	6.59e-05	0.00034	CcSEcCtD
Bismuth Subsalicylate—Oedema—Dexamethasone—hematologic cancer	6.59e-05	0.00034	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Irinotecan—hematologic cancer	6.58e-05	0.00034	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mitoxantrone—hematologic cancer	6.58e-05	0.00034	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Carmustine—hematologic cancer	6.58e-05	0.00034	CcSEcCtD
Bismuth Subsalicylate—Infection—Dexamethasone—hematologic cancer	6.54e-05	0.000338	CcSEcCtD
Bismuth Subsalicylate—Infection—Betamethasone—hematologic cancer	6.54e-05	0.000338	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vincristine—hematologic cancer	6.53e-05	0.000337	CcSEcCtD
Bismuth Subsalicylate—Rash—Carmustine—hematologic cancer	6.53e-05	0.000337	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Carmustine—hematologic cancer	6.52e-05	0.000336	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Alitretinoin—hematologic cancer	6.52e-05	0.000336	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—hematologic cancer	6.51e-05	0.000336	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Prednisolone—hematologic cancer	6.51e-05	0.000336	CcSEcCtD
Bismuth Subsalicylate—Headache—Carmustine—hematologic cancer	6.48e-05	0.000335	CcSEcCtD
Bismuth Subsalicylate—Rash—Alitretinoin—hematologic cancer	6.47e-05	0.000334	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Alitretinoin—hematologic cancer	6.46e-05	0.000333	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Ifosfamide—hematologic cancer	6.44e-05	0.000332	CcSEcCtD
Bismuth Subsalicylate—Headache—Alitretinoin—hematologic cancer	6.42e-05	0.000331	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Gemcitabine—hematologic cancer	6.41e-05	0.000331	CcSEcCtD
Bismuth Subsalicylate—Nausea—Thalidomide—hematologic cancer	6.4e-05	0.00033	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Triamcinolone—hematologic cancer	6.39e-05	0.00033	CcSEcCtD
Bismuth Subsalicylate—Rash—Ifosfamide—hematologic cancer	6.39e-05	0.00033	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Ifosfamide—hematologic cancer	6.38e-05	0.000329	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—hematologic cancer	6.38e-05	0.000329	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Irinotecan—hematologic cancer	6.36e-05	0.000328	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Etoposide—hematologic cancer	6.36e-05	0.000328	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Etoposide—hematologic cancer	6.33e-05	0.000326	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—hematologic cancer	6.32e-05	0.000326	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—hematologic cancer	6.29e-05	0.000325	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vincristine—hematologic cancer	6.28e-05	0.000324	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Betamethasone—hematologic cancer	6.28e-05	0.000324	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Dexamethasone—hematologic cancer	6.28e-05	0.000324	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Prednisolone—hematologic cancer	6.27e-05	0.000324	CcSEcCtD
Bismuth Subsalicylate—Rash—Vincristine—hematologic cancer	6.23e-05	0.000321	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vincristine—hematologic cancer	6.22e-05	0.000321	CcSEcCtD
Bismuth Subsalicylate—Pain—Triamcinolone—hematologic cancer	6.21e-05	0.00032	CcSEcCtD
Bismuth Subsalicylate—Headache—Vincristine—hematologic cancer	6.19e-05	0.000319	CcSEcCtD
Bismuth Subsalicylate—Nausea—Carmustine—hematologic cancer	6.15e-05	0.000317	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—hematologic cancer	6.14e-05	0.000317	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mitoxantrone—hematologic cancer	6.12e-05	0.000316	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Irinotecan—hematologic cancer	6.12e-05	0.000316	CcSEcCtD
Bismuth Subsalicylate—Nausea—Alitretinoin—hematologic cancer	6.09e-05	0.000314	CcSEcCtD
Bismuth Subsalicylate—Rash—Mitoxantrone—hematologic cancer	6.07e-05	0.000313	CcSEcCtD
Bismuth Subsalicylate—Rash—Irinotecan—hematologic cancer	6.07e-05	0.000313	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mitoxantrone—hematologic cancer	6.06e-05	0.000313	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Irinotecan—hematologic cancer	6.06e-05	0.000313	CcSEcCtD
Bismuth Subsalicylate—Headache—Mitoxantrone—hematologic cancer	6.03e-05	0.000311	CcSEcCtD
Bismuth Subsalicylate—Headache—Irinotecan—hematologic cancer	6.03e-05	0.000311	CcSEcCtD
Bismuth Subsalicylate—Nausea—Ifosfamide—hematologic cancer	6.02e-05	0.000311	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Triamcinolone—hematologic cancer	5.98e-05	0.000309	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Cisplatin—hematologic cancer	5.98e-05	0.000308	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—hematologic cancer	5.97e-05	0.000308	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Gemcitabine—hematologic cancer	5.96e-05	0.000307	CcSEcCtD
Bismuth Subsalicylate—Rash—Gemcitabine—hematologic cancer	5.91e-05	0.000305	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Gemcitabine—hematologic cancer	5.9e-05	0.000305	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—hematologic cancer	5.89e-05	0.000304	CcSEcCtD
Bismuth Subsalicylate—Erythema—Methotrexate—hematologic cancer	5.87e-05	0.000303	CcSEcCtD
Bismuth Subsalicylate—Headache—Gemcitabine—hematologic cancer	5.87e-05	0.000303	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vincristine—hematologic cancer	5.87e-05	0.000303	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—hematologic cancer	5.84e-05	0.000301	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Dexamethasone—hematologic cancer	5.8e-05	0.000299	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Betamethasone—hematologic cancer	5.8e-05	0.000299	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Triamcinolone—hematologic cancer	5.77e-05	0.000298	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—hematologic cancer	5.75e-05	0.000297	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Triamcinolone—hematologic cancer	5.74e-05	0.000296	CcSEcCtD
Bismuth Subsalicylate—Oedema—Prednisone—hematologic cancer	5.74e-05	0.000296	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Betamethasone—hematologic cancer	5.73e-05	0.000295	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dexamethasone—hematologic cancer	5.73e-05	0.000295	CcSEcCtD
Bismuth Subsalicylate—Nausea—Irinotecan—hematologic cancer	5.72e-05	0.000295	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mitoxantrone—hematologic cancer	5.72e-05	0.000295	CcSEcCtD
Bismuth Subsalicylate—Infection—Prednisone—hematologic cancer	5.7e-05	0.000294	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Etoposide—hematologic cancer	5.66e-05	0.000292	CcSEcCtD
Bismuth Subsalicylate—Pain—Dexamethasone—hematologic cancer	5.63e-05	0.000291	CcSEcCtD
Bismuth Subsalicylate—Pain—Betamethasone—hematologic cancer	5.63e-05	0.000291	CcSEcCtD
Bismuth Subsalicylate—Nausea—Gemcitabine—hematologic cancer	5.57e-05	0.000287	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Cisplatin—hematologic cancer	5.55e-05	0.000287	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—hematologic cancer	5.52e-05	0.000285	CcSEcCtD
Bismuth Subsalicylate—Rash—Cisplatin—hematologic cancer	5.51e-05	0.000284	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Cisplatin—hematologic cancer	5.5e-05	0.000284	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—hematologic cancer	5.5e-05	0.000284	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Etoposide—hematologic cancer	5.48e-05	0.000283	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Prednisone—hematologic cancer	5.47e-05	0.000282	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—hematologic cancer	5.45e-05	0.000281	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Dexamethasone—hematologic cancer	5.43e-05	0.00028	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Betamethasone—hematologic cancer	5.43e-05	0.00028	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—hematologic cancer	5.38e-05	0.000278	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Etoposide—hematologic cancer	5.29e-05	0.000273	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Dexamethasone—hematologic cancer	5.23e-05	0.00027	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Betamethasone—hematologic cancer	5.23e-05	0.00027	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Prednisolone—hematologic cancer	5.22e-05	0.000269	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Betamethasone—hematologic cancer	5.21e-05	0.000269	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Dexamethasone—hematologic cancer	5.21e-05	0.000269	CcSEcCtD
Bismuth Subsalicylate—Nausea—Cisplatin—hematologic cancer	5.19e-05	0.000268	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Triamcinolone—hematologic cancer	5.14e-05	0.000265	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Etoposide—hematologic cancer	5.09e-05	0.000263	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—hematologic cancer	5.09e-05	0.000262	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Prednisone—hematologic cancer	5.05e-05	0.000261	CcSEcCtD
Bismuth Subsalicylate—Rash—Etoposide—hematologic cancer	5.05e-05	0.00026	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Etoposide—hematologic cancer	5.04e-05	0.00026	CcSEcCtD
Bismuth Subsalicylate—Headache—Etoposide—hematologic cancer	5.01e-05	0.000259	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Prednisone—hematologic cancer	4.99e-05	0.000257	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—hematologic cancer	4.98e-05	0.000257	CcSEcCtD
Bismuth Subsalicylate—Rash—Prednisolone—hematologic cancer	4.98e-05	0.000257	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Prednisolone—hematologic cancer	4.97e-05	0.000257	CcSEcCtD
Bismuth Subsalicylate—Headache—Prednisolone—hematologic cancer	4.95e-05	0.000255	CcSEcCtD
Bismuth Subsalicylate—Constipation—Prednisone—hematologic cancer	4.91e-05	0.000253	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Methotrexate—hematologic cancer	4.83e-05	0.000249	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Triamcinolone—hematologic cancer	4.8e-05	0.000248	CcSEcCtD
Bismuth Subsalicylate—Infection—Methotrexate—hematologic cancer	4.76e-05	0.000246	CcSEcCtD
Bismuth Subsalicylate—Nausea—Etoposide—hematologic cancer	4.75e-05	0.000245	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Prednisone—hematologic cancer	4.73e-05	0.000244	CcSEcCtD
Bismuth Subsalicylate—Nausea—Prednisolone—hematologic cancer	4.69e-05	0.000242	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Dexamethasone—hematologic cancer	4.66e-05	0.00024	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Betamethasone—hematologic cancer	4.66e-05	0.00024	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Triamcinolone—hematologic cancer	4.62e-05	0.000238	CcSEcCtD
Bismuth Subsalicylate—Rash—Triamcinolone—hematologic cancer	4.58e-05	0.000236	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Triamcinolone—hematologic cancer	4.57e-05	0.000236	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Methotrexate—hematologic cancer	4.57e-05	0.000236	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Prednisone—hematologic cancer	4.56e-05	0.000235	CcSEcCtD
Bismuth Subsalicylate—Headache—Triamcinolone—hematologic cancer	4.55e-05	0.000235	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Prednisone—hematologic cancer	4.53e-05	0.000234	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—hematologic cancer	4.52e-05	0.000233	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Dexamethasone—hematologic cancer	4.51e-05	0.000233	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Betamethasone—hematologic cancer	4.51e-05	0.000233	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—hematologic cancer	4.49e-05	0.000231	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—hematologic cancer	4.46e-05	0.00023	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Dexamethasone—hematologic cancer	4.36e-05	0.000225	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Betamethasone—hematologic cancer	4.36e-05	0.000225	CcSEcCtD
Bismuth Subsalicylate—Nausea—Triamcinolone—hematologic cancer	4.31e-05	0.000222	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Epirubicin—hematologic cancer	4.28e-05	0.000221	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Methotrexate—hematologic cancer	4.26e-05	0.00022	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—hematologic cancer	4.22e-05	0.000218	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Betamethasone—hematologic cancer	4.19e-05	0.000216	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Dexamethasone—hematologic cancer	4.19e-05	0.000216	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—hematologic cancer	4.19e-05	0.000216	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—hematologic cancer	4.17e-05	0.000215	CcSEcCtD
Bismuth Subsalicylate—Rash—Dexamethasone—hematologic cancer	4.15e-05	0.000214	CcSEcCtD
Bismuth Subsalicylate—Rash—Betamethasone—hematologic cancer	4.15e-05	0.000214	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—hematologic cancer	4.15e-05	0.000214	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Betamethasone—hematologic cancer	4.15e-05	0.000214	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Dexamethasone—hematologic cancer	4.15e-05	0.000214	CcSEcCtD
Bismuth Subsalicylate—Headache—Dexamethasone—hematologic cancer	4.13e-05	0.000213	CcSEcCtD
Bismuth Subsalicylate—Headache—Betamethasone—hematologic cancer	4.13e-05	0.000213	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—hematologic cancer	4.12e-05	0.000213	CcSEcCtD
Bismuth Subsalicylate—Pain—Methotrexate—hematologic cancer	4.1e-05	0.000212	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Prednisone—hematologic cancer	4.06e-05	0.000209	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Epirubicin—hematologic cancer	3.99e-05	0.000206	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—hematologic cancer	3.96e-05	0.000204	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—hematologic cancer	3.95e-05	0.000204	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—hematologic cancer	3.95e-05	0.000204	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Prednisone—hematologic cancer	3.92e-05	0.000203	CcSEcCtD
Bismuth Subsalicylate—Nausea—Betamethasone—hematologic cancer	3.91e-05	0.000202	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dexamethasone—hematologic cancer	3.91e-05	0.000202	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—hematologic cancer	3.9e-05	0.000201	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—hematologic cancer	3.84e-05	0.000198	CcSEcCtD
Bismuth Subsalicylate—Constipation—Epirubicin—hematologic cancer	3.84e-05	0.000198	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Methotrexate—hematologic cancer	3.81e-05	0.000197	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Prednisone—hematologic cancer	3.79e-05	0.000196	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—hematologic cancer	3.79e-05	0.000196	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—hematologic cancer	3.7e-05	0.000191	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—hematologic cancer	3.69e-05	0.00019	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—hematologic cancer	3.65e-05	0.000189	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Prednisone—hematologic cancer	3.65e-05	0.000188	CcSEcCtD
Bismuth Subsalicylate—Rash—Prednisone—hematologic cancer	3.62e-05	0.000187	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Prednisone—hematologic cancer	3.61e-05	0.000186	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—hematologic cancer	3.61e-05	0.000186	CcSEcCtD
Bismuth Subsalicylate—Headache—Prednisone—hematologic cancer	3.59e-05	0.000185	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—hematologic cancer	3.56e-05	0.000184	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—hematologic cancer	3.55e-05	0.000183	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—hematologic cancer	3.55e-05	0.000183	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—hematologic cancer	3.55e-05	0.000183	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—hematologic cancer	3.42e-05	0.000177	CcSEcCtD
Bismuth Subsalicylate—Nausea—Prednisone—hematologic cancer	3.41e-05	0.000176	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Methotrexate—hematologic cancer	3.39e-05	0.000175	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Doxorubicin—hematologic cancer	3.3e-05	0.00017	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—hematologic cancer	3.28e-05	0.000169	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—hematologic cancer	3.28e-05	0.000169	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Epirubicin—hematologic cancer	3.17e-05	0.000164	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Methotrexate—hematologic cancer	3.17e-05	0.000164	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—hematologic cancer	3.07e-05	0.000158	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Methotrexate—hematologic cancer	3.05e-05	0.000157	CcSEcCtD
Bismuth Subsalicylate—Rash—Methotrexate—hematologic cancer	3.02e-05	0.000156	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—hematologic cancer	3.02e-05	0.000156	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—hematologic cancer	3e-05	0.000155	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Epirubicin—hematologic cancer	2.97e-05	0.000153	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Doxorubicin—hematologic cancer	2.94e-05	0.000152	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Epirubicin—hematologic cancer	2.85e-05	0.000147	CcSEcCtD
Bismuth Subsalicylate—Nausea—Methotrexate—hematologic cancer	2.85e-05	0.000147	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—hematologic cancer	2.84e-05	0.000147	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—hematologic cancer	2.83e-05	0.000146	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—hematologic cancer	2.83e-05	0.000146	CcSEcCtD
Bismuth Subsalicylate—Headache—Epirubicin—hematologic cancer	2.81e-05	0.000145	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Doxorubicin—hematologic cancer	2.75e-05	0.000142	CcSEcCtD
Bismuth Subsalicylate—Nausea—Epirubicin—hematologic cancer	2.66e-05	0.000138	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Doxorubicin—hematologic cancer	2.64e-05	0.000136	CcSEcCtD
Bismuth Subsalicylate—Rash—Doxorubicin—hematologic cancer	2.62e-05	0.000135	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—hematologic cancer	2.62e-05	0.000135	CcSEcCtD
Bismuth Subsalicylate—Headache—Doxorubicin—hematologic cancer	2.6e-05	0.000134	CcSEcCtD
Bismuth Subsalicylate—Nausea—Doxorubicin—hematologic cancer	2.47e-05	0.000127	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Disease—DKK1—hematologic cancer	1.39e-05	0.000122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.39e-05	0.000122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NUP98—hematologic cancer	1.38e-05	0.000121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT5B—hematologic cancer	1.38e-05	0.000121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—MTR—hematologic cancer	1.38e-05	0.000121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCG2—hematologic cancer	1.38e-05	0.000121	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—FHL2—hematologic cancer	1.37e-05	0.00012	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—IDH1—hematologic cancer	1.36e-05	0.000119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	1.36e-05	0.000119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CST3—hematologic cancer	1.35e-05	0.000118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ENO2—hematologic cancer	1.35e-05	0.000118	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AGRN—hematologic cancer	1.35e-05	0.000118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.35e-05	0.000118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ADCY7—hematologic cancer	1.34e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTO1—hematologic cancer	1.34e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TXN—hematologic cancer	1.34e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCC3—hematologic cancer	1.34e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL2—hematologic cancer	1.34e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NUP214—hematologic cancer	1.33e-05	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HGF—hematologic cancer	1.32e-05	0.000116	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SPHK1—hematologic cancer	1.31e-05	0.000115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTT1—hematologic cancer	1.31e-05	0.000115	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CSF2—hematologic cancer	1.31e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTR—hematologic cancer	1.31e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—XIAP—hematologic cancer	1.31e-05	0.000114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.29e-05	0.000113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SDC1—hematologic cancer	1.28e-05	0.000112	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ENO2—hematologic cancer	1.28e-05	0.000112	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—IDH2—hematologic cancer	1.28e-05	0.000112	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HMMR—hematologic cancer	1.28e-05	0.000112	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SMARCA4—hematologic cancer	1.27e-05	0.000111	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—JAK1—hematologic cancer	1.26e-05	0.00011	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PRKCG—hematologic cancer	1.26e-05	0.00011	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—UGT1A1—hematologic cancer	1.26e-05	0.00011	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.24e-05	0.000108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC22A1—hematologic cancer	1.23e-05	0.000107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CRABP1—hematologic cancer	1.23e-05	0.000107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.22e-05	0.000107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SDC1—hematologic cancer	1.22e-05	0.000106	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.21e-05	0.000106	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.2e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ARNTL—hematologic cancer	1.2e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALOX5—hematologic cancer	1.2e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.2e-05	0.000105	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.18e-05	0.000103	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2RA—hematologic cancer	1.18e-05	0.000103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—LCK—hematologic cancer	1.18e-05	0.000103	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SRC—hematologic cancer	1.17e-05	0.000102	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA9—hematologic cancer	1.17e-05	0.000102	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ACP5—hematologic cancer	1.17e-05	0.000102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NUP98—hematologic cancer	1.16e-05	0.000101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.16e-05	0.000101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—H3F3A—hematologic cancer	1.15e-05	0.000101	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NCOR2—hematologic cancer	1.15e-05	0.000101	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	1.14e-05	9.97e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PDGFB—hematologic cancer	1.14e-05	9.95e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NCOA3—hematologic cancer	1.13e-05	9.84e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ADCY7—hematologic cancer	1.13e-05	9.84e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRKCZ—hematologic cancer	1.12e-05	9.8e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NUP214—hematologic cancer	1.12e-05	9.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.11e-05	9.67e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CDK2—hematologic cancer	1.1e-05	9.66e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CALR—hematologic cancer	1.1e-05	9.63e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—IDH1—hematologic cancer	1.1e-05	9.61e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTR—hematologic cancer	1.09e-05	9.57e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCG2—hematologic cancer	1.09e-05	9.57e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CD44—hematologic cancer	1.09e-05	9.53e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NQO1—hematologic cancer	1.09e-05	9.53e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCC3—hematologic cancer	1.09e-05	9.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TXN—hematologic cancer	1.09e-05	9.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTO1—hematologic cancer	1.09e-05	9.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PARP1—hematologic cancer	1.08e-05	9.47e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	1.08e-05	9.43e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ENO2—hematologic cancer	1.07e-05	9.38e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.07e-05	9.33e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FBXW7—hematologic cancer	1.07e-05	9.32e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SPHK1—hematologic cancer	1.06e-05	9.29e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK14—hematologic cancer	1.06e-05	9.26e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	1.05e-05	9.15e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HDAC2—hematologic cancer	1.04e-05	9.14e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CXCR4—hematologic cancer	1.04e-05	9.14e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTT1—hematologic cancer	1.04e-05	9.1e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD44—hematologic cancer	1.03e-05	9.03e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYCS—hematologic cancer	1.03e-05	9.02e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—FN1—hematologic cancer	1.03e-05	8.98e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.03e-05	8.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HSP90AA1—hematologic cancer	1.02e-05	8.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—UGT1A1—hematologic cancer	1.02e-05	8.93e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CBL—hematologic cancer	1.02e-05	8.9e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SDC1—hematologic cancer	1.02e-05	8.9e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.01e-05	8.83e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CRABP1—hematologic cancer	9.94e-06	8.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC22A1—hematologic cancer	9.94e-06	8.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CG—hematologic cancer	9.83e-06	8.59e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	9.72e-06	8.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HSP90AA1—hematologic cancer	9.71e-06	8.49e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ALOX5—hematologic cancer	9.68e-06	8.47e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PTPN11—hematologic cancer	9.65e-06	8.44e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	9.6e-06	8.39e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NUP98—hematologic cancer	9.38e-06	8.2e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT1—hematologic cancer	9.37e-06	8.19e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	9.22e-06	8.06e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	9.18e-06	8.02e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CREBBP—hematologic cancer	9.11e-06	7.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ADCY7—hematologic cancer	9.1e-06	7.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NCOA3—hematologic cancer	9.1e-06	7.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTP1—hematologic cancer	9.09e-06	7.95e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NUP214—hematologic cancer	9.04e-06	7.9e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.95e-06	7.82e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	8.9e-06	7.78e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCG2—hematologic cancer	8.86e-06	7.74e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTR—hematologic cancer	8.86e-06	7.74e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	8.8e-06	7.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GRB2—hematologic cancer	8.76e-06	7.66e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFA—hematologic cancer	8.74e-06	7.64e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ENO2—hematologic cancer	8.69e-06	7.59e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NQO1—hematologic cancer	8.65e-06	7.56e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CD44—hematologic cancer	8.65e-06	7.56e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CD—hematologic cancer	8.64e-06	7.55e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KITLG—hematologic cancer	8.62e-06	7.53e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCB1—hematologic cancer	8.61e-06	7.52e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	8.47e-06	7.41e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTT1—hematologic cancer	8.42e-06	7.36e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT5A—hematologic cancer	8.42e-06	7.36e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NCOR1—hematologic cancer	8.35e-06	7.3e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTM1—hematologic cancer	8.35e-06	7.3e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN2B—hematologic cancer	8.35e-06	7.3e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8.29e-06	7.25e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SDC1—hematologic cancer	8.23e-06	7.2e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYCS—hematologic cancer	8.19e-06	7.16e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3R1—hematologic cancer	8.16e-06	7.13e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HSP90AA1—hematologic cancer	8.14e-06	7.11e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD86—hematologic cancer	8.08e-06	7.06e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HES1—hematologic cancer	7.96e-06	6.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—JAK2—hematologic cancer	7.93e-06	6.93e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NCOR1—hematologic cancer	7.92e-06	6.92e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.89e-06	6.89e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.86e-06	6.88e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGF1—hematologic cancer	7.83e-06	6.85e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FOXO1—hematologic cancer	7.72e-06	6.75e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFRB—hematologic cancer	7.7e-06	6.73e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFRA—hematologic cancer	7.58e-06	6.63e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—JAK1—hematologic cancer	7.56e-06	6.61e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRKCG—hematologic cancer	7.56e-06	6.61e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CB—hematologic cancer	7.53e-06	6.58e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.43e-06	6.49e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—MTHFR—hematologic cancer	7.38e-06	6.45e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.32e-06	6.4e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	7.27e-06	6.36e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTP1—hematologic cancer	7.22e-06	6.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NQO1—hematologic cancer	7e-06	6.12e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CD44—hematologic cancer	7e-06	6.12e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTHFR—hematologic cancer	7e-06	6.12e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.98e-06	6.1e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—hematologic cancer	6.98e-06	6.1e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HLA-A—hematologic cancer	6.98e-06	6.1e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2—hematologic cancer	6.92e-06	6.05e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.85e-06	5.99e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCB1—hematologic cancer	6.83e-06	5.97e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFB—hematologic cancer	6.81e-06	5.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TSC2—hematologic cancer	6.66e-06	5.82e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NCOR1—hematologic cancer	6.63e-06	5.8e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTM1—hematologic cancer	6.63e-06	5.8e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYCS—hematologic cancer	6.62e-06	5.79e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HSP90AA1—hematologic cancer	6.58e-06	5.75e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.51e-06	5.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGFR3—hematologic cancer	6.4e-06	5.6e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EP300—hematologic cancer	6.21e-06	5.42e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CG—hematologic cancer	6.2e-06	5.42e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BAD—hematologic cancer	6.07e-06	5.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SRC—hematologic cancer	6.03e-06	5.28e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOTCH1—hematologic cancer	6.01e-06	5.26e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.92e-06	5.18e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD80—hematologic cancer	5.89e-06	5.15e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KIT—hematologic cancer	5.88e-06	5.14e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—hematologic cancer	5.88e-06	5.14e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTHFR—hematologic cancer	5.86e-06	5.12e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTP1—hematologic cancer	5.84e-06	5.1e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—hematologic cancer	5.8e-06	5.07e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTPN11—hematologic cancer	5.78e-06	5.05e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CREBBP—hematologic cancer	5.75e-06	5.03e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.65e-06	4.94e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CREB1—hematologic cancer	5.6e-06	4.89e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MAPK3—hematologic cancer	5.56e-06	4.86e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BRAF—hematologic cancer	5.53e-06	4.83e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCB1—hematologic cancer	5.53e-06	4.83e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6R—hematologic cancer	5.46e-06	4.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CD—hematologic cancer	5.45e-06	4.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CREBBP—hematologic cancer	5.45e-06	4.77e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TGFB1—hematologic cancer	5.39e-06	4.72e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ALB—hematologic cancer	5.38e-06	4.71e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTM1—hematologic cancer	5.37e-06	4.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NCOR1—hematologic cancer	5.37e-06	4.69e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAP2K1—hematologic cancer	5.2e-06	4.55e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CD—hematologic cancer	5.17e-06	4.52e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.17e-06	4.52e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3R1—hematologic cancer	5.15e-06	4.5e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—hematologic cancer	5e-06	4.37e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGF2—hematologic cancer	4.95e-06	4.33e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CG—hematologic cancer	4.92e-06	4.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3R1—hematologic cancer	4.88e-06	4.27e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CB—hematologic cancer	4.75e-06	4.16e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—JAK2—hematologic cancer	4.74e-06	4.15e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTHFR—hematologic cancer	4.74e-06	4.15e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MDM2—hematologic cancer	4.63e-06	4.05e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—hematologic cancer	4.59e-06	4.01e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CREBBP—hematologic cancer	4.57e-06	3.99e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CB—hematologic cancer	4.51e-06	3.94e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTOR—hematologic cancer	4.51e-06	3.94e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CD4—hematologic cancer	4.5e-06	3.93e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—hematologic cancer	4.44e-06	3.88e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CD—hematologic cancer	4.33e-06	3.78e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ALB—hematologic cancer	4.27e-06	3.74e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—hematologic cancer	4.25e-06	3.71e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1B—hematologic cancer	4.23e-06	3.7e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.18e-06	3.65e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—hematologic cancer	4.11e-06	3.59e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3R1—hematologic cancer	4.09e-06	3.57e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CG—hematologic cancer	3.98e-06	3.48e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—EP300—hematologic cancer	3.92e-06	3.42e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1A—hematologic cancer	3.9e-06	3.41e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—hematologic cancer	3.89e-06	3.4e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CB—hematologic cancer	3.77e-06	3.3e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—hematologic cancer	3.75e-06	3.28e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EP300—hematologic cancer	3.71e-06	3.25e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CREBBP—hematologic cancer	3.69e-06	3.23e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SRC—hematologic cancer	3.61e-06	3.16e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CD—hematologic cancer	3.5e-06	3.06e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—STAT3—hematologic cancer	3.48e-06	3.04e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—hematologic cancer	3.47e-06	3.04e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MAPK3—hematologic cancer	3.33e-06	2.91e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3R1—hematologic cancer	3.31e-06	2.89e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—hematologic cancer	3.26e-06	2.85e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—hematologic cancer	3.24e-06	2.83e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TGFB1—hematologic cancer	3.23e-06	2.82e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—EP300—hematologic cancer	3.11e-06	2.72e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CB—hematologic cancer	3.05e-06	2.67e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—hematologic cancer	2.99e-06	2.61e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—hematologic cancer	2.9e-06	2.53e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—hematologic cancer	2.75e-06	2.4e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—hematologic cancer	2.64e-06	2.31e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—hematologic cancer	2.54e-06	2.22e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—EP300—hematologic cancer	2.52e-06	2.2e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—IL6—hematologic cancer	2.43e-06	2.13e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—hematologic cancer	2.37e-06	2.07e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—hematologic cancer	2.3e-06	2.01e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—hematologic cancer	2.24e-06	1.96e-05	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—hematologic cancer	1.88e-06	1.64e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—hematologic cancer	1.86e-06	1.63e-05	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—hematologic cancer	1.52e-06	1.33e-05	CbGpPWpGaD
